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Abstract 4 
Signaling pathways often share molecular components, tying the activity of one pathway 5 
to the functioning of another. In the NFkB signaling system distinct kinases mediate 6 
inflammatory and developmental signaling via RelA and RelB, respectively. Though the 7 
substrates of the developmental, so called non-canonical, pathway are induced by 8 
inflammatory/canonical signaling, crosstalk is limited. Through dynamical systems 9 
modeling we identified the underlying regulatory mechanism. We found that as the 10 
substrate of the non-canonical kinase NIK, the nfkb2 gene product p100, transitions 11 
from a monomer to a multimeric complex it may compete with and inhibit p100 12 
processing to the active p52. While multimeric complexes of p100 (IkBδ) are known to 13 
inhibit pre-existing RelA:p50 through sequestration, here we report that p100 complexes 14 
can inhibit the enzymatic formation of RelB:p52. We show that the dose response 15 
systems properties of this ‘complex substrate competition’ motif are poorly accounted 16 
for by standard Michaelis-Menten kinetics but require more detailed mass action 17 
formulations. In sum, while tonic inflammatory signaling is required for adequate 18 
expression of the non-canonical pathway precursors, the complex substrate competition 19 
motif identified here can prevent amplification of the active RelB:p52 dimer in elevated 20 
inflammatory conditions to ensure reliable RelB-dependent developmental signaling 21 
independent of inflammatory context.  22 
 23 
Significance 24 
Inflammation-responsive canonical NFκB induces many genes, two of which encode 25 
non-canonical NFκB pathway components that control developmental processes. This 26 
suggests potentially perilous cross-regulation by which inflammatory conditions could 27 
derail immune organ developmental decisions. We use mathematical modeling to 28 
propose a mechanism that functions as a brake on this connection. We report that the 29 
key enzyme mediating developmental NFκB is subject to competition from two forms of 30 
its single substrate. Termed “substrate complex competition”, this regulatory motif can 31 
lead to a counterintuitive decrease of signaling product in conditions of elevated 32 
substrate abundance. We propose that while non-canonical NFκB requires intact 33 
inflammatory NFκB signaling, substrate complex competition allows developmental 34 
signals to be reliably transduced without inappropriate amplification by inflammation. 35 
\body 36 
Introduction 37 
Signaling pathways are typically thought of as self-contained, receiving a stimulus from 38 
a receptor and producing a downstream effect.  However, their molecular components 39 
often participate in multiple pathways resulting in highly networked signaling systems (1-40 
3). Interconnected signaling pathways have the potential for stimuli of one pathway to 41 
alter the dose-response of another pathway, commonly referred to as signaling 42 
crosstalk. Crosstalk has been identified as an important mechanism by which robust 43 
regulation is maintained (4), or signals are amplified or fine-tuned (5), but also as a 44 
potential route by which defined perturbations have broad effects that may lead to 45 
cancer (6, 7). Therefore, defining the mechanisms that insulate from potential crosstalk 46 
is of key importance to understanding regulation and misregulation of signaling in health 47 
and disease. 48 
 49 
NFκB signaling is induced by a wide variety of signals that are transduced by two 50 
kinases, the canonical pathway is mediated by NFκB Essential Modulator (NEMO)-51 
containing IKK, while the non-canonical pathway is mediated by NFκB Inducible Kinase 52 
(NIK) (8). The canonical pathway is rapidly induced by a variety of inflammatory 53 
cytokines and pathogens and through NEMO-dependent degradation of NFκB inhibitors 54 
(IκBα/β/ε), which results in nuclear localization of pre-existing, transcriptionally active 55 
NFκB dimers (predominantly RelA:p50). The non-canonical NFκB pathway leads to the 56 
de novo generation of RelB:p52, which controls the developmental maturation of 57 
immune cells and organs (9, 10). Developmental and survival stimuli (mediated by 58 
LTbR, CD40, BAFFR, RANK, TNFR2, CD27) activate NIK-dependent p100 processing 59 
to produce p52, which dimerizes with RelB to produce transcriptionally active RelB:p52. 60 
Disruption of RelB:p52 formation, through perturbing p100, RelB or NIK impacts 61 
peripheral lymphoid organ development, dendritic and B-cell maturation, mammary 62 
gland development, and osteoclast maturation (11-15).  Conversely, constitutive hyper-63 
activity of the non-canonical pathway is associated with broad inflammatory, 64 
autoimmune, and malignant pathologies (16, 17).  65 
 66 
Whereas the prevailing role of the non-canonical NFκB pathway is in controlling 67 
development, organogenesis and tissue homeostasis, the canonical NFkB pathway 68 
functions in an acute, transient manner triggered by pathogen or inflammatory 69 
cytokine exposure (16). Yet, the two pathways are strongly interconnected, as the 70 
non-canonical pathway may amplify canonical activation in B-cells (18) and in 71 
dendritic cells (19). Conversely, canonical pathway activity controls the expression of 72 
the two genes that encode the RelB:p52 dimer, i.e. relb and nfkb2 (20). Indeed, 73 
genetic knockouts of canonical pathway mediators such as NEMO, IKK2 or RelA, 74 
abrogate the ability of the non-canonical pathway to produce RelB:p52 activity (21, 75 
22). Thus there is potential for cross-regulation that may result in substantially 76 
elevated non-canonical NFkB (RelB:p52) activity in elevated inflammatory conditions 77 
that would derail normal tissue homeostasis. Fortunately, this is not the case: the 78 
debilitating phenotypes observed in hyper-active non-canonical pathway mutants (17, 79 
23) are not observed in inflammatory conditions or in constitutively active mutants of 80 
canonical pathway components (24). This suggests that there is a regulatory brake 81 
that limits the extent by which canonical pathway can modulate non-canonical 82 
pathway activity. However, the mechanistic basis of this brake remains unknown. 83 
 84 
Here we investigate how insulation between canonical and non-canonical pathway 85 
activity is achieved to ensure that inflammatory signals do not adversely affect 86 
developmental homeostasis of immune cells and organs. Using dynamical systems 87 
modeling we discover and characterize a regulatory motif in which the critical signal-88 
transducing kinase is presented with alternate complexes of the substrate, resulting in 89 
‘substrate complex competition’. This, in turn, modulates the enzymatic substrate-to-90 
product dose response in a manner that may result in an effective insulation of one 91 
pathway from the other. 92 
 93 
Results 94 
A computational model of NFκB predicts amplification of non-canonical RelB:p52 95 
by canonical pathway activity 96 
To investigate crosstalk between the canonical and non-canonical NFκB pathways an 97 
established mathematical model of NFκB signaling (25) was extended to include 98 
canonical-pathway-induced p100 and RelB synthesis, along with NIK-dependent p100 99 
to p52 processing (Figure 1A). This network topology has potential for the canonical 100 
(inflammatory) pathway to amplify non-canonical (developmental) signals mediated by 101 
RelB:p52. Indeed, computational simulations of this network predicted that canonical 102 
pathway induction (reflected in p100 mRNA levels) substantially induces not only the 103 
canonical RelA:p50 dimer but also the non-canonical RelB:p52 dimer (Figure 1B).  104 
 105 
While canonical pathway activity does indeed induce both p100 (nfkb2) and RelB 106 
mRNA in MEFs (22) (Figure 1C),  amplification of the transcriptionally active RelB:p52 107 
protein dimer, as predicted by the computational simulation, is not observed 108 
experimentally (Figure 1C, Mukherjee, et al. (26)). Similarly in B cells nfkb2 mRNA is 109 
induced by canonical pathway activity but amplification of RelB:p52 is not seen (18). 110 
Indeed, such amplification would be deleterious to developmental processes in the 111 
context of chronic inflammation (18, 22, 26). To establish why the computationally-112 
identified potential for substantial crosstalk is not realized, and examine the discrepancy 113 
between mRNA induction and protein dimer formation, mechanistically more detailed 114 
mathematical models of NIK-mediated reactions were constructed (Figure 1D and E).  115 
 116 
The dose response of the non-canonical NFκB monomer p52 to increasing canonical 117 
pathway activity was characterized:  a typically saturating dose-response curve of p52 118 
to increasing p100 mRNA was observed whether p100 processing was represented by 119 
a Michaelis-Menten equation (Figure 1D) or mass-action kinetics of two-step enzymatic 120 
binding and processing reactions (Figure 1E).  121 
 122 
Competition between distinct forms of NIK’s substrate can lead to an inverted 123 
dose-response regime 124 
P100, if not processed into p52, forms higher-molecular weight NFκB-inhibitory 125 
complexes, also known as IκBδ-containing IκBsomes (27-29). It was shown that, upon 126 
p100 homodimerization via the rel homology domain, one monomer’s ankyrin repeat 127 
domain self-inhibits the dimer and the other remains available to inhibit an NFκB dimer 128 
in trans. While newly synthesized monomeric p100 can be processed into p52 by NIK, 129 
the exposed ankyrin repeat domain of the p100 homodimer (IκBδ) is degraded in a NIK-130 
dependent manner, leaving only a self-inhibited non-functional p100:p52 heterodimer.  131 
We represent p100:p100 processing to non-functional p100:p52 as complete 132 
degradation of IκBδ, consistent with previous mathematical models (30, 31). 133 
Simulations with a model of NIK-mediated p100 processing into p52 based on 134 
Michaelis-Menten kinetics predicted no change to the dose-response of p52 with the 135 
addition of NIK’s role in the degradation of IκBδ (Figure 1F). However, when these 136 
reactions were modeled using a two-step formulation with mass-action kinetics (binding 137 
and catalysis by the enzyme), p52 first reaches a lower maximal level and then shows 138 
an inverted dose-response relationship with increasing substrate (p100 mRNA), 139 
resulting in decreased product (p52) (Figure 1G). At the stationary point of maximal p52, 140 
either increasing or decreasing canonical signaling strength will reduce p52 abundance.  141 
Formulating the reactions with detailed mass action kinetics revealed that the free NIK 142 
concentrations available for processing one substrate complex can be affected by its 143 
processing of the other; specifically, NIK binding to multimeric p100 (IκBδ) excludes it 144 
from binding newly synthesized monomeric p100. We refer to this process as substrate 145 
complex competition. While single substrate dose-response relationships were 146 
indistinguishable in Michaelis-Menten models of a single enzyme-mediated reaction and 147 
two-step mass-action representations, they differed when two substrate complexes 148 
were considered, regardless of the values in p100 dimerization kinetics, NIK enzymatic 149 
activities, and IκBδ degradation rates (SI Appendix, Figure S1). The non-monotonic 150 
dose-response of substrate complex competition is also observed when degradation of 151 
NIK after enzymatic activity is included to capture the possibility of a negative feedback 152 
loop by which IKKα that has been activated by NIK can in turn phosphorylate and 153 
destabilizes NIK (SI Appendix, Figure S2 and S3, Razani, et al. (32)).   154 
 155 
NIK abundance determines whether substrate complex competition occurs 156 
To probe the mechanism further, we examined the control of the stationary point on the 157 
p52 dose-response curve with parameter scans of p100 mRNA ((p100t, which we used 158 
as an indicator of canonical pathway/NEMO activity) over a wide variety of NIK 159 
concentrations (Figure 2A). Expectedly, in a regime lacking NIK, p52 was not produced 160 
at any level of p100 mRNA as p100 processing is NIK-dependent. At a wide range of 161 
intermediate NIK levels, initial increases of p100 mRNA resulted in increasing p52 as 162 
NIK binds to nascent p100 (Figure 2A and B). After the initial increase in p52, as NIK 163 
begins to reach saturation, more unprocessed p100 forms IκBδ resulting in NIK-IκBδ 164 
complexes, which compete with nascent p100 for NIK binding (Figure 2B). This 165 
substrate complex competition results in a decrease in p52 formation. In a regime with 166 
excess NIK (>16 fold higher than published parameters (18)), NIK does not reach 167 
saturation, enabling complete processing of all nascent p100 into p52, and no IκBδ is 168 
predicted to form with increasing canonical pathway activity (Figure 2A). Thus, the 169 
excess NIK regime is predicted to show monotonic crosstalk as all increases in 170 
canonical pathway activity result in increased p52 production. However, for a wide 171 
range of NIK abundances (around the published kinetic parameters (18)) biphasic 172 
crosstalk is predicted with the canonical pathway, boosting p52 production at the low 173 
end, and diminishing p52 production at the high end (Figure 2A).  174 
 175 
Interestingly, for B cells cultured in BAFF, published kinetic parameters predict that 176 
canonical pathway activity is approximately optimal for peak p52 production; both 177 
decreases and increases in canonical pathway activity would lead to reduced p52 178 
generation due to either reduced substrate availability or substrate complex competition 179 
(Figure 2A and B).  However, when NIK abundances are further elevated, higher p100 180 
mRNA levels are required to saturate NIK, and higher maximal NIK-p100 abundances 181 
are obtained (Figure 2C). In the 16-fold range of NIK abundances around the published 182 
parameters there is a fundamental limit on NIK-p100 complex formation resulting from 183 
substrate complex competition, which limits crosstalk and ensures that p52 can only be 184 
substantially induced by increasing NIK concentration through the non-canonical 185 
pathway. 186 
 187 
While the regime of NIK activity determined by previously published parameters (18) 188 
indicates a substantial role of substrate complex competition, we sought to generate an 189 
experimentally testable prediction to further explore its biological relevance. Through a 190 
time-course simulation of increasing p100 mRNA (resulting from canonical NFκB 191 
pathway activity) we predicted that substrate-competition leads to NIK switching 192 
substrates from nascent monomeric p100 to IκBδ resulting in a decrease in p52 193 
generation coinciding with an increase in p100 (mainly in the multimeric p100 form of 194 
IκBδ) (Figure 2D and SI Appendix S4). Indeed, when B cells cultured in the presence of 195 
the non-canonical stimulus BAFF are stimulated with canonical NFκB pathway stimulus 196 
anti-IgM, the substantial constitutive levels of p52 then decrease between 8 and 25 197 
hours while p100 increases (Figure 2E)(18). This time-course closely matches the one 198 
predicted by the computational model. The mechanism for this p52 decrease is NIK 199 
switching from predominantly binding to nascent p100 (which results in p52 production) 200 
to predominantly binding to IκBδ (Figure 2D). We conclude that in B-cells NIK activity 201 
was indeed in the concentration regime predicted by published parameters in which NIK 202 
becomes substrate saturated when cells are stimulated by canonical stimuli. Therefore, 203 
we identified substrate complex competition as a novel potential mechanism of reducing 204 
non-canonical pathway activity in response to canonical signals. 205 
 206 
Substrate complex competition can insulate RelB:p52 from canonical pathway 207 
crosstalk by reversing the dose-response of p52 208 
While the reduced model allowed us to investigate the potential for a biphasic dose-209 
response curve due to substrate complex competition, we next investigated the impact 210 
of this proposed mechanism on formation of the transcriptionally active NFκB dimer 211 
RelB:p52.  Like 100, RelB is a target gene of canonical NFκB (RelA:p50) activity (Figure 212 
1C), but unlike p52, it does not require processing. The working model was therefore 213 
extended to include inducible expression of RelB in order to investigate how the non-214 
monotonic dose response of p52 (due to substrate complex competition) and the 215 
monotonic dose response of RelB combine to control RelB:p52 activity (Figure 3A). 216 
 217 
As expected, simulations showed that increasing NEMO kinase activity led to increases 218 
of p52 at the low range but decreases in the high range (Figure 3B), whereas RelB 219 
levels increased substantially, as seen in multiple experimental systems (Figure 1C). An 220 
elevated level of NIK activity could shift the saturation point to allow for more p52 221 
generation. Interestingly, the combined result of RelB and p52 responses to increasing 222 
canonical pathway activity is that while RelB is strongly induced, the decreasing 223 
availability of p52 due to substrate complex competition does not result in hyper-224 
activation of RelB:p52, which remains largely unchanged when compared to the 225 
magnitude of RelB:p52 induction effected by non-canonical pathway activation (Figure 226 
3B and 1C). Only severe deficiency in canonical pathway activity was predicted to 227 
substantially diminish RelB:p52 activity due to lack of both monomers. 228 
 229 
To test whether this emergent property accurately reflects experimentally measured 230 
responses to canonical and non-canonical stimuli we scanned both pathway activation 231 
strengths from absence to normal basal, to ~5 fold over basal (Figure 3C). We found 232 
that induction of NIK is expected to strongly induce RelB:p52, but, interestingly, the 233 
model predicted that combining NIK activation with activation of the canonical kinase 234 
NEMO would further induce RelB but not the RelB:p52 dimer due to substrate complex 235 
competition limiting the generation of p52. This finding is robust to the fold change in 236 
half-life that occurs when monomeric p100 and p52 dimerize into a more stable 237 
RelB:p52 heterodimer (SI Appendix, Figure S5). Indeed, comparing this prediction to 238 
experimentally measured nuclear RelB:p52 in B cells stimulated with NIK-activating 239 
stimuli BAFF and co-stimulation with the addition of NEMO-activating stimuli anti-IgM 240 
confirmed no amplification of RelB:p52 by co-activation of the canonical pathway activity 241 
(Figure 3D quantified from published data (18), compared to Figure 3C RelB:p52 plot). 242 
Remarkably, the slight reduction in RelB:p52 with canonical co-stimulation predicted by 243 
the model is reproduced in these experimental conditions. The model also predicts that 244 
RelB:p52 formation is abolished, even in response to NIK activation, if basal canonical 245 
pathway activity is removed (Figure 3C). Indeed, this is experimentally confirmed, as in 246 
MEFs, genetically deficient in IKKβ (a component of the canonical NEMO IκB-kinase 247 
complex), RelB:p52 is diminished and cannot be induced by NIK-activating stimuli 248 
(Figure 3D).   249 
 250 
Overall, RelB:p52 activity levels are predominantly controlled by NIK with a requirement 251 
for a minimal level of canonical signaling to avoid substrate and RelB limitation. We 252 
term this requirement for basal NEMO signaling as licensing, since basal canonical 253 
signals enable non-canonical signaling. However, elevated canonical activity was 254 
unable to further amplify it. Indeed, in the high canonical activity regime, the 255 
combination of opposite dose-response curves of p52 and RelB results in an effective 256 
insulation of non-canonical RelB:p52 from canonical RelA:p50 transcription factors.  257 
 258 
Discussion 259 
Biological signaling pathways consist rarely of linear cascades of enzymes, but rather of 260 
a complex networks of enzymes that act on multiple molecular substrates. Given the 261 
high potential for regulatory crosstalk, how systems achieve pathway insulation leading 262 
to the robust and predictable responses required to maintain homeostasis and health, is 263 
an important question. 264 
 265 
Here we have proposed a novel mechanism, one that substantially modifies the 266 
expected dose response curve between two pathways. The mechanism is termed 267 
“substrate complex competition”, in which an enzyme’s substrate has the propensity to 268 
form a complex that may also be recognized by the enzyme but does not lead to the 269 
functionally active product. Thus excess expression of the substrate will lead to build up 270 
of the competing complex, and a reduction in enzymatic flux and product. While 271 
substrate competition, in which catalysis of one substrate inhibits an enzyme’s ability to 272 
catalyze other substrates has been described (33, 34), the motif described here is 273 
distinct in that a single substrate is capable of forming alternate forms (oligomeric 274 
complexes) that lead to functionally distinct products. This feature alone leads to the 275 
striking non-monotonic dose-response relationship described here. A non-monotonic 276 
dose-response relationship has previously been described to require substantially more 277 
complex regulatory networks including expression of additional inhibitors, feedback 278 
mechanisms or multiple phosphorylation states (35).  279 
 280 
It was opined that enzymes within signal-transduction pathways may not always satisfy 281 
preconditions of Michaelis-Menten kinetics, including the requirement that substrate 282 
concentration greatly exceeds enzyme concentration (36). In the case of NIK (also 283 
known as MAK3K14), whose specific activity is not regulated (via post-translational 284 
phosphorylation) unlike other MAP3K family members, both enzyme concentration 285 
(determined by regulating its degradation) and substrate concentration (determined by 286 
canonical pathway activity) are highly variable.  We showed that the Michaelis-Menten 287 
equation accurately accounts NIK’s dose response without substrate complex 288 
formation; however, the Michaelis-Menten formulation fails to recapitulate the effects of 289 
substrate complex competition and renders incorrect dose-response relationships when 290 
multiple functionally distinct substrate isoforms impinge on the same enzyme. To 291 
account for substrate complex competition with a Michaelis-Menten rate equation each 292 
oligomeric complex of the substrate would need to be modelled as a competing 293 
substrate (SI Appendix, Figure S6), and cannot be recreated by perturbing parameters 294 
within the standard Michaelis-Menten representation (SI Appendix, Figure S1) (34).  295 
Interestingly, marked distinctions between Michaelis-Menten and step-wise 296 
representations have been observed in the canonical MAPK signaling cascade (37); 297 
however, these resulted in a quantitative difference in dose-ranges (rather than the 298 
qualitatively reversed dose response seen here) and resulted from a distinct mechanism 299 
(conserved moieties rather than substrate complex competition). Here we highlight that, 300 
while a model formulation may be valid for a process in isolation, when combining 301 
models (for example for generating whole cell simulations, (38)), enzyme behavior could 302 
be qualitatively different in the context of multiple converging substrates or substrate 303 
complexes. 304 
 305 
It is known that multimeric complexes of p100 (termed IκBδ-containing IκBsomes or 306 
kappaBsomes) can sequester pre-existing NFkB (e.g. RelA:p50 and cRel:p50) in the 307 
cytoplasm in a stochiometric manner, similar to IκBα, β and ε (18, 19, 27, 28), Here we 308 
found that, through substrate complex competition, IκBδ may also kinetically compete 309 
for NIK and reduce the processing of precursor p100 into p52. This direct enzyme-310 
mediated brake on NFκB RelB:p52 formation may prevent canonical signaling from 311 
amplifying non-canonical signaling independently of IκBδ-mediated NFkB sequestration.  312 
 313 
While substrate complex competition alone does not necessarily diminish signaling 314 
crosstalk, within the NFκB signaling network it may. The reason is that the genes of 315 
both constituents of the non-canonical dimeric RelB:p52 transcription factor are induced 316 
by increasing canonical pathway activity; substrate competition reverses the dose-317 
response of one, thus rendering the dimeric combination of the two, the dimer RelB:p52, 318 
remarkably independent of canonical pathway activity, unless that activity is 319 
substantially abrogated.  As such, we propose a mechanism through which the non-320 
canonical pathway is licensed by basal canonical activity, but that additional canonical 321 
activity does not further amplify RelB:p52 (Figure 3C). The result is that cells receiving 322 
developmental non-canonical NFkB signals (e.g. LTb, BAFF, RANKL) can reliably 323 
respond regardless of the inflammatory condition. In other words, even chronic 324 
inflammatory conditions do not derail the normal developmental programs that rely of 325 
non-canonical NFkB activity unless the mechanisms ensuring complex substrate 326 
competition are inactivated (23).  327 
 328 
 329 
Materials and Methods 330 
Initial computational investigations (Figure 1B) were carried out using an established 331 
model as described in SI Appendix, Methods (25). A novel computational model of only 332 
NIK-mediated reactions with mass action and Michaelis-Menten kinetics (Figure 1D-G) 333 
was constructed, and analyzed using COPASI (39). Plots were created in MATLAB 334 
(The Mathworks Inc.). Model equations and methodology are provided in the SI 335 
Appendix. Parameters and initial conditions are provided in SI Appendix, Table 1 and 2. 336 
Models are available in COPASI and SBML format at 337 
(http://www.signalingsystems.ucla.edu/models-and-code/nik/), and on BioModels (40) 338 
with the following identifiers: 339 
- Michaelis-Menten p52 processing only (Figure 1D): MODEL1903280001. 340 
- Mass action, p52 processing only (Figure 1E): MODEL1903280002. 341 
- Michaelis-Menten, p52 and IκBδ processing (Figure 1F): MODEL1904020002. 342 
- Mass action, p52 and IκBδ processing – substrate complex competition motif (Figure 343 
1G): MODEL1904020003. 344 
- Mass action, p52 and IκBδ processing, with RelB (Figure 3B): MODEL1904030001.  345 
Acknowledgements 346 
We thank Kim Ngo, Tsuyoshi Mikkaichi, Ying Tang and Pedro Mendes for valuable 347 
discussions. The work was funded by NIH grants (AH) R01AI132731 and R01AI127867. 348 
References 349 
 350 
1. Chavali S, Barrenas F, Kanduri K, & Benson M (2010) Network properties of 351 
human disease genes with pleiotropic effects. BMC systems biology 4(1):78. 352 
2. Gandhi TK, et al. (2006) Analysis of the human protein interactome and 353 
comparison with yeast, worm and fly interaction datasets. Nature genetics 354 
38(3):285-293. 355 
3. Shih VF-S, Tsui R, Caldwell A, & Hoffmann A (2011) A single NFκB system for 356 
both canonical and non-canonical signaling. Cell research 21(1):86. 357 
4. Ramos HJ & Gale M, Jr. (2011) RIG-I like receptors and their signaling crosstalk 358 
in the regulation of antiviral immunity. Current opinion in virology 1(3):167-176. 359 
5. De Nardo D, De Nardo CM, Nguyen T, Hamilton JA, & Scholz GM (2009) 360 
Signaling crosstalk during sequential TLR4 and TLR9 activation amplifies the 361 
inflammatory response of mouse macrophages. Journal of immunology 362 
(Baltimore, Md. : 1950) 183(12):8110-8118. 363 
6. Guo S, Liu M, & Gonzalez-Perez RR (2011) Role of Notch and its oncogenic 364 
signaling crosstalk in breast cancer. Biochimica et biophysica acta 1815(2):197-365 
213. 366 
7. Han SS, et al. (2010) NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B 367 
lymphoma. Molecular cancer 9:97. 368 
8. Mitchell S, Vargas J, & Hoffmann A (2016) Signaling via the NFκB system. Wiley 369 
Interdisciplinary Reviews: Systems Biology and Medicine 8(3):227-241. 370 
9. Weih F, et al. (1995) Multiorgan inflammation and hematopoietic abnormalities in 371 
mice with a targeted disruption of RelB, a member of the NF-κB/Rel family. Cell 372 
80(2):331-340. 373 
10. Sun SC (2012) The noncanonical NF-κB pathway. Immunological reviews 374 
246(1):125-140. 375 
11. Yilmaz ZB, Weih DS, Sivakumar V, & Weih F (2003) RelB is required for Peyer's 376 
patch development: differential regulation of p52–RelB by lymphotoxin and TNF. 377 
The EMBO journal 22(1):121-130. 378 
12. Demicco EG, et al. (2005) RelB/p52 NF-κB complexes rescue an early delay in 379 
mammary gland development in transgenic mice with targeted superrepressor 380 
IκB-α expression and promote carcinogenesis of the mammary gland. Molecular 381 
and cellular biology 25(22):10136-10147. 382 
13. Cormier F, et al. (2013) Frequent engagement of RelB activation is critical for cell 383 
survival in multiple myeloma. PloS one 8(3):e59127. 384 
14. Claudio E, Brown K, Park S, Wang H, & Siebenlist U (2002) BAFF-induced 385 
NEMO-independent processing of NF-κB2 in maturing B cells. Nature 386 
immunology 3(10):958. 387 
15. Franzoso G, et al. (1997) Requirement for NF-κB in osteoclast and B-cell 388 
development. Genes & development 11(24):3482-3496. 389 
16. Cildir G, Low KC, & Tergaonkar V (2016) Noncanonical NF-κB signaling in health 390 
and disease. Trends in molecular medicine 22(5):414-429. 391 
17. Ishikawa H, Carrasco D, Claudio E, Ryseck R-P, & Bravo R (1997) Gastric 392 
hyperplasia and increased proliferative responses of lymphocytes in mice lacking 393 
the COOH-terminal ankyrin domain of NF-κB2. Journal of Experimental Medicine 394 
186(7):999-1014. 395 
18. Almaden JV, et al. (2014) A Pathway Switch Directs BAFF Signaling to Distinct 396 
NFκB Transcription Factors in Maturing and Proliferating B Cells. Cell reports 397 
9(6):2098-2111. 398 
19. Shih VF, et al. (2012) Control of RelB during dendritic cell activation integrates 399 
canonical and noncanonical NF-κB pathways. Nature immunology 13(12):1162. 400 
20. Basak S & Hoffmann A (2008) Crosstalk via the NF-κB signaling system. 401 
Cytokine & growth factor reviews 19(3-4):187-197. 402 
21. Müller JR & Siebenlist U (2003) Lymphotoxin β receptor induces sequential 403 
activation of distinct NF-κB factors via separate signaling pathways. Journal of 404 
Biological Chemistry 278(14):12006-12012. 405 
22. Basak S, Shih VF-S, & Hoffmann A (2008) Generation and activation of multiple 406 
dimeric transcription factors within the NF-κB signaling system. Molecular and 407 
cellular biology 28(10):3139-3150. 408 
23. Wang Z, Zhang B, Yang L, Ding J, & Ding H-F (2008) Constitutive production of 409 
NF-κB2 p52 is not tumorigenic but predisposes mice to inflammatory 410 
autoimmune disease by repressing Bim expression. Journal of Biological 411 
Chemistry 283(16):10698-10706. 412 
24. Sasaki Y, et al. (2006) Canonical NF-κB activity, dispensable for B cell 413 
development, replaces BAFF-receptor signals and promotes B cell proliferation 414 
upon activation. Immunity 24(6):729-739. 415 
25. Werner SL, Barken D, & Hoffmann A (2005) Stimulus specificity of gene 416 
expression programs determined by temporal control of IKK activity. Science 417 
309(5742):1857-1861. 418 
26. Mukherjee T, et al. (2017) A TNF-p100 pathway subverts noncanonical NF-κB 419 
signaling in inflamed secondary lymphoid organs. The EMBO 420 
journal:e201796919. 421 
27. Tao Z, et al. (2014) p100/IκBδ sequesters and inhibits NF-κB through 422 
kappaBsome formation. Proceedings of the National Academy of Sciences 423 
111(45):15946-15951. 424 
28. Basak S, et al. (2007) A fourth IκB protein within the NF-κB signaling module. 425 
Cell 128(2):369-381. 426 
29. Savinova OV, Hoffmann A, & Ghosh G (2009) The Nfkb1 and Nfkb2 proteins 427 
p105 and p100 function as the core of high-molecular-weight heterogeneous 428 
complexes. Molecular cell 34(5):591-602. 429 
30. Yılmaz ZB, et al. (2014) Quantitative dissection and modeling of the NF-κB p100-430 
p105 module reveals interdependent precursor proteolysis. Cell reports 431 
9(5):1756-1769. 432 
31. Shih VF-S, et al. (2009) Kinetic control of negative feedback regulators of NF-433 
κB/RelA determines their pathogen-and cytokine-receptor signaling specificity. 434 
Proceedings of the National Academy of Sciences 106(24):9619-9624. 435 
32. Razani B, et al. (2010) Negative feedback in noncanonical NF-κB signaling 436 
modulates NIK stability through IKKα-mediated phosphorylation. Science 437 
signaling 3(123):ra41. 438 
33. Hopkins M, Tyson JJ, & Novak B (2017) Cell cycle transitions: a common role for 439 
stoichiometric inhibitors. Molecular biology of the cell. 440 
34. Schäuble S, Stavrum AK, Puntervoll P, Schuster S, & Heiland I (2013) Effect of 441 
substrate competition in kinetic models of metabolic networks. FEBS letters 442 
587(17):2818-2824. 443 
35. Suwanmajo T & Krishnan J (2013) Biphasic responses in multi-site 444 
phosphorylation systems. Journal of The Royal Society Interface 445 
10(89):20130742. 446 
36. Chen WW, Niepel M, & Sorger PK (2010) Classic and contemporary approaches 447 
to modeling biochemical reactions. Genes & development 24(17):1861-1875. 448 
37. Markevich NI, Hoek JB, & Kholodenko BN (2004) Signaling switches and 449 
bistability arising from multisite phosphorylation in protein kinase cascades. The 450 
Journal of cell biology 164(3):353-359. 451 
38. Karr Jonathan R, et al. (2012) A Whole-Cell Computational Model Predicts 452 
Phenotype from Genotype. Cell 150(2):389-401. 453 
39. Hoops S, et al. (2006) COPASI—a complex pathway simulator. Bioinformatics 454 
22(24):3067-3074. 455 
40. Chelliah V, et al. (2014) BioModels: ten-year anniversary. Nucleic acids research 456 
43(D1):D542-D548. 457 
  
 Figure Legends 
 
Figure 1 Substrate complex competition results in reduced product formation 
with increasing substrate. A. Schematic of the computational model adapted from 
Werner et al. 2005 (25) with the addition of NFkB-responsive synthesis of p100 and 
RelB, NIK-mediated processing of p100 to p52, and subsequent p52 binding to RelB. 
Each reaction (represented by an arrow) is represented by an ODE. In the absence of 
stimulation, canonical NFκB RelA:p50 is predominantly bound to IκBs. In response to 
canonical stimuli, IκBα/β/ε are degraded in a NEMO-dependent manner, releasing 
NFκB RelA:p50 to the nucleus where it activates transcription of IκBs forming a 
feedback loop, as well as p100 and RelB. P100 is processed into p52 in a NIK-
dependent manner in response to non-canonical stimuli, which can then bind RelB to 
form RelB:p52 and translocate to the nucleus. B. Heatmaps of simulated steady-state 
concentrations of nuclear RelA:p50 and RelB:p52 as a function of canonical and non-
canonical signaling strengths. C. Experimentally determined time-course line graphs of 
relb and nfkb2 (encodes p100 protein) mRNA induction in MEFs (left) and B cells (right) 
in response to canonical-pathway-activating stimuli TNFα (left) and anti-IgM (right). MEF 
data is quantified Basak, et al. (22), B cell data from Almaden, et al. (18). Bar graphs 
show RelB:p52 induction quantified by Mukherjee, et al. (26) and Almaden, et al. (18). D 
and E. Schematic (left) and steady-state concentration of p52 (right) as a function of 
p100 mRNA concentrations as predicted by computational models of NIK-mediated 
p100 processing based on Michaelis-Menten kinetics (D) or mass action kinetics (E). F 
and G. Schematic (left) and steady-state concentration of p52 and IκBδ (right) as a 
function of p100 mRNA concentrations as predicted by computational models of NIK-
mediated p100 processing and IκBδ degradation based on Michaelis-Menten kinetics 
(F) or mass action kinetics (G). IκBδ is modeled as p100 dimer (double-headed arrow). 
The substrate complex competition motif is described by panel G. 
 
Figure 2 Canonical NFκB signaling reduces p52 due to substrate complex 
competition. A. Three dimensional surface plot of simulated steady-state concentration 
of p52 as a function of increasing p100 mRNA concentrations and relative NIK levels 
using the mass action model depicted in panel 1G . A red line indicates reported basal 
levels of NIK activity, with the reported basal p100 mRNA level indicated with a thick 
mark (18). Here, p100 mRNA is an indicator of canonical NFκB RelA:p50 activity. B. 
Heatmaps of the simulated concentrations of NIK-p100 and NIK-IκBδ complexes, 
generated as in A. C. Scatter plot showing the relationship between the concentrations 
of NIK-IκBδ and NIK-p100 complexes for different levels of NIK, as p100 mRNA levels 
were increased (color scale). Shown are values from the first point in a timecourse 
simulation when p52 exceeds 200nM. The full parameter range was scanned for every 
NIK concentration but only simulations where p52 exceeded 200nM are shown. Basal 
NIK activity is indicated with a black border with the thick mark indicating the basal p100 
mRNA concentration. D. Line plots of simulated timecourse concentrations of NIK-p100 
and NIK-IκBδ complexes (left) and p100 and p52 proteins (right) in response to 
canonical pathway activity using the p100 mRNA input curve shown in SI Appendix, 
Figure S3. Concentrations were normalized to their maximum value. p100 was plotted 
as the sum of all molecular species containing p100 for consistency with experimental 
assays (p100, NIK-p100, IκBδ and NIK-IκBδ). E. Line graphs from quantified 
Immunoblots of whole-cell p52 and p100 expression in wild-type B cells stimulated with 
anti-IgM reported by Almaden, et al. (18).  
 
Figure 3.  Transcriptionally active RelB:p52 requires, but is not amplified by, 
canonical NFκB RelA:p50 activity. A. Schematic representing the extended model of 
RelB and p100 induction by canonical pathway activity. B. Line graphs of simulated 
steady-state p52 (left), RelB (middle) and RelB:p52 (right) in response to increasing 
NEMO activity (represented by increasing p100 mRNA and RelB expression). Dose-
responses are shown for simulations with no NIK activity (thin line), basal NIK 
(moderate line thickness) activity and 2-fold increased NIK activity over basal (thicker 
line). Basal NEMO and NIK activities are indicated with a black square. Here, p100 
mRNA production is used as an indicator of canonical pathway activity. C. Heatmaps of 
simulated steady-state p52 (left) RelB (middle) and RelB:p52 (right) over a parameter 
scan of NIK activity and NEMO activity. Basal NEMO and NIK activities are indicated 
with a white square. Horizontal arrow indicates increases from basal NIK. Increasing 
vertical arrow indicates the predicted effect of canonical pathway co-stimulation. 
Decreasing vertical arrow indicates the predicted effect of the reduction of basal 
canonical pathway activity. D. Left: Time course of RelB:p52 NFkB DNA-binding 
activities in B cells stimulated with BAFF alone (non-canonical stimulation), and anti-IgM 
(canonical pathway stimulation) plus BAFF quantified from Almaden, et al. (18). Right: 
Time course of RelB:p52 NFkB DNA-binding activities in WT and IKKβ-/- (canonical 
pathway kinase knockout) MEFs stimulated with α-LTβR (non-canonical stimulation).  
